ABUS vs GILD: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABUS and GILD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABUS and GILD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Arbutus Biopharma is a clinical-stage biopharmaceutical company that leverages deep virology expertise to develop novel therapeutics aimed at a functional cure for chronic hepatitis B virus (cHBV), a disease affecting hundreds of millions of people worldwide for which current treatments rarely cure. Its lead candidate is imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNAi (RNA interference) therapeutic designed to suppress all HBV antigens, including surface antigen (HBsAg), and it is being studied in combination regimens. Arbutus has reported that a number of patients across its Phase 2a IM-PROVE trials achieved a functional cure when imdusiran was combined with standard antivirals plus agents like pegylated interferon or low-dose immunotherapy, and in 2026 the FDA granted imdusiran Fast Track designation. A second candidate, AB-101, is an oral PD-L1 inhibitor in early clinical testing meant to reawaken the immune response against HBV.

Full ABUS guide

Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Its HIV franchise, anchored by widely used single-tablet regimens like Biktarvy and the long-acting prevention drug for pre-exposure prophylaxis, generates the bulk of its revenue and is a global standard of care. Gilead also has a significant presence in liver diseases, including hepatitis B and C, where its cures transformed treatment, and in COVID-19 with the antiviral remdesivir. More recently, Gilead has expanded into oncology through acquisitions, building a portfolio in cell therapy (CAR-T) and antibody-drug conjugates for cancers such as breast and bladder cancer. The company makes money by selling these prescription medicines worldwide, supported by patents and strong pricing. Headquartered in Foster City, California, Gilead generates substantial cash flow from its HIV base, pays a solid dividend, and is investing to diversify into oncology and other areas as it manages future patent expirations.

Full GILD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABUS drivers: Imdusiran functional-cure program; Moderna settlement and cash.
• GILD drivers: Dominant HIV franchise; Oncology expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. For GILD, gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABUS if you believe its drivers more; GILD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABUS and GILD guides.

ABUS. These figures are approximate and tied to the Jul 2026 asOf date; verify live trial status, settlement terms and receipts, and cash figures against Arbutus's latest quarterly filings before acting. Traditional valuation multiples do not apply cleanly to a pre-revenue biotech: the stock is driven by clinical data, regulatory milestones, and, unusually here, the litigation settlement cash, so earnings snapshots are less meaningful than pipeline progress and balance-sheet strength.

GILD. Gilead is valued as a mature, cash-generative biopharma with a dominant HIV base and a solid dividend, rather than a high-growth name. Investors weigh durable virology cash flows and capital return against limited overall growth and uncertainty in oncology. Reported earnings can swing with acquisition-related charges, so investors often focus on underlying product revenue and free cash flow.

Headline figures (approximate, Jul 2026): ABUS shows stage Clinical-stage biotech; no meaningful product revenue, lead asset Imdusiran (AB-729), RNAi for chronic hepatitis B, Phase 2a, FDA Fast Track, second asset AB-101, oral PD-L1 inhibitor, early clinical, moderna settlement $2.25B global settlement (noncontingent ~$950M plus ~$1.3B contingent); Arbutus expects ~$178.7M share in mid-2026 (verify live); GILD shows revenue (ttm) ~$28 to 30 billion, operating margin ~thirties percent (varies with charges), net income (ttm) ~variable, affected by acquisition charges, dividend yield ~3 to 4%.

ABUS and GILD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABUS and GILD exposure against your real portfolio. It is not an investment adviser.